No Data
No Data
Declining Stock and Decent Financials: Is The Market Wrong About Pacira BioSciences, Inc. (NASDAQ:PCRX)?
Jefferies Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $36
Jefferies analyst Glen Santangelo maintains $Pacira BioSciences(PCRX.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success rate of 51.1% a
Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX)
Pacira BioSciences(PCRX.US) Officer Sells US$114.02K in Common Stock
$Pacira BioSciences(PCRX.US)$ Officer RIKER LAUREN sold 3,970 shares of common stock on Jun 12, 2024 at an average price of $28.72 for a total value of $114.02K.Source: Announcement What is statement
Pacira BioSciences(PCRX.US) Officer Sells US$143.19K in Common Stock
$Pacira BioSciences(PCRX.US)$ Officer SLONIN JONATHAN sold 5,012 shares of common stock on Jun 11, 2024 at an average price of $28.57 for a total value of $143.19K.Source: Announcement What is stateme
Pacira BioSciences(PCRX.US) Officer Sells US$28,380 in Common Stock
$Pacira BioSciences(PCRX.US)$ Officer GAUGLER DARYL sold 1,000 shares of common stock on Jun 13, 2024 at an average price of $28.38 for a total value of $28,380.Source: Announcement What is statement